FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the field of organic chemistry, namely to heterocyclic compounds of the general formula or to their pharmaceutically acceptable salts, where R1a, R1b, R1c and R1d are independently selected from the group, consisting of hydrogen and halogen; R2 is selected from the group, consisting of phenyl, substituted with 1 or 2 halogen atoms; R3 is selected from the group, consisting of C1-C5alkyl and (C5cycloalkyl)C1alkyl; R4 represents hydrogen; R5 represents
, where each of: R12a, R12b, R12c and R12d represents hydrogen; R13 represents hydrogen; R14 is selected from the group, consisting of hydrogen and C1-C6alkyl; Z is selected from the group, consisting of -OR15 and -NR16aR16b; or Z and R14 together form a carbonyl group; R15 and R16b represent hydrogen; R16a represents -SO2R16c; R16c represents C1alkyl; o equals 1 or 2; p equals 1 or 2; X represents NR'; Y represents NR"; R' and R" represent hydrogen; and
represents a single or a double bond. The invention also relates to a pharmaceutical composition based on the formula I compound, methods of cancer treatment and a set based on the formula I compound.
EFFECT: obtained are novel heterocyclic compounds, useful in the treatment of hyperproliferative disorders.
17 cl, 32 dwg, 32 tbl, 11 ex
Title | Year | Author | Number |
---|---|---|---|
MDM2 PROTEIN DESTRUCTORS | 2017 |
|
RU2743432C2 |
AMYLOID-BINDING AGENTS | 2010 |
|
RU2517174C2 |
N- (PHENYLSULPHONYL) BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | 2017 |
|
RU2744358C2 |
N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | 2017 |
|
RU2722560C1 |
CAFFEIC ACID BIOLOGICALLY AVAILABLE FOR ORAL USE, ASSOCIATED WITH ANTITUMOUR MEDICINAL AGENTS | 2007 |
|
RU2456265C2 |
ENPP1 INHIBITORS AND METHODS OF MODULATING THE IMMUNE RESPONSE | 2018 |
|
RU2800798C2 |
METHOD OF ENHANCEMENT OF CHEMOTHERAPEUTIC AGENT CYTOTOXICITY, SET FOR TREATMENT | 1994 |
|
RU2148406C1 |
PHENYLCARBAMATES AND USE THEREOF AS ENZYME INHIBITORS OF HYDROLASES OF FATTY ACID AMIDES (FAAH) AND DOPAMINE RECEPTOR D3 (D3DR) MODULATORS | 2014 |
|
RU2693457C2 |
TAXANE DERIVATIVES, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT | 1994 |
|
RU2137764C1 |
CFTR REGULATORS AND METHODS OF USING | 2016 |
|
RU2730855C2 |
Authors
Dates
2015-06-10—Published
2010-11-10—Filed